



Crescendo Biologics Wins “Best Established Biotech Company” at the 2021 OBN Awards

Cambridge, UK, 26 November 2021 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, is pleased to announce it won the “Best Established Biotech Company” award at last night’s OBN Awards.

The team at Crescendo was nominated for its strong progress over the last several years, including the initiation of the clinical programme of CB307, a novel half-life extended CD137 x PSMA Humabody®, as well as for numerous milestones achieved, including within its collaborations with Takeda and Zai Lab.

Theodora Harold, CEO of Crescendo, commented: “We are honoured that our achievements have been recognized by the judging panel at this year’s OBN Awards. It is a testament to our team’s hard work in developing our portfolio of T cell enhancing therapies for the benefit of cancer patients. We are very proud to receive the industry-wide recognition and to be part of such a vibrant community of exciting bioscience companies.”

The OBN Award ceremony was held at the University of Oxford’s Ashmolean Museum and included 36 short-listed companies across 11 categories. Other finalists for the “Best Established Biotech Company” award included Healx and C4X Discovery.

-Ends-

For more information, please contact:

Crescendo Biologics

Michael Booth, CFO
+ 44 (0)1223 497140
investors@crescendobiologics.com
media@crescendobiologics.com

Instinctif Partners

Melanie Toyne-Sewell, Katie Duffell,
Nathan Billis
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody® for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours.



The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Beyond Crescendo's proprietary pipeline, the Company has a global, multi-target discovery and development collaboration with Takeda; a clinical development partnership with Cancer Research UK; and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001), an anti-IL-17A targeting Humabody®, which has recently successfully completed a Phase 1 clinical trial.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit www.crescendobiologics.com and follow [@HUMABODY](https://twitter.com/HUMABODY).